Our intangible assets related to license agreements are subject to amortization and are amortized using the straight-line method over their estimated useful life.

We acquired license and supply agreements in relation to cytisinicline upon the acquisition of Extab, on May 18, 2015. The agreements were determined to have a fair value of $3.1 million with an estimated useful life of 14 years.

The components of intangible assets were as follows (in thousands):


	June 30, 2026							December 31, 2025
	Gross Carrying		Accumulated			Net Carrying		Gross Carrying		Accumulated			Net Carrying
	Value		Amortization			Value		Value		Amortization			Value
License Agreements	$	3,117	$	(2,477	)	$	640	$	3,117	$	(2,366	)	$	751

For the three and six months ended June 30, 2026 we recorded license agreement amortization expense of $0.1 million and $0.1 million, respectively. For the three and six months ended June 30, 2025 we recorded license agreement amortization expense of $0.1 million and $0.1 million, respectively. The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2026 (in thousands):


Year Ending December 31,
2026		112
2027		223
2028		223
2029		82
Total	$	640

We acquire internet domain names to prevent their use by competitors and to protect our brand from third-party use. The domain names are not actively used in our operations. Accordingly, the asset has been classified as a defensive intangible asset in accordance with ASC 350-30.

Although we have no current plan to actively use the domains and the underlying registrations are indefinitely renewable, the assets do

not qualify for an indefinite useful life. We estimated a useful life of 14 years based on the expected period over which the domains' defensive values are expected to continue and indirectly benefit us. The assets are amortized on a straight-line basis over this period.

As of June 30, 2026, the domain name intangible assets consisted of the following:


	June 30, 2026							December 31, 2025
	Gross Carrying		Accumulated			Net Carrying		Gross Carrying		Accumulated		Net Carrying
	Value		Amortization			Value		Value		Amortization		Value
Domain Names	$	170	$	(1	)	$	169	$	—	$	—	$	—

The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2026 (in thousands):


Year Ending December 31,
2026		6
2027		12
2028		12
2029		12
2030		12
Thereafter		115
Total	$	169

Intangible Assets Impairment Analysis

We evaluate the carrying amount of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful life or that indicate the asset may be impaired. We conducted an analysis of potential impairment indicators for long lived assets, including the license and supply agreements for the active pharmaceutical ingredient cytisinicline and Domain Name Defensive Intangible Assets, and concluded that there were no indicators of impairment identified as of June 30, 2026.